Skip to main content

P11-282 Registry Protocol A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA (Adalimumab) in Patients with Moderately to Severely Active Ulcerative Colitis (UC).

NCT01848561

A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA (Adalimumab) in Patients with Moderately to Severely Active Ulcerative Colitis (UC).

Associated Conditions

Colon

Principal Investigator

Sponsor

AbbVie

A non-interventional Registry study to evaluate the long-term safety and effectiveness of HUMIRA as used in routine clinical practice in adult patients (18 years of age or older) with moderately to severely active UC, who receive anti-TNF therapy according to routine clinical practice. This Registry is part of post-marketing commitments to the European Medicines Agency (EMA) and the Food and Drug Administration (FDA).